| Varicose veins of lower extremity
Asclera vs Sotradecol
Side-by-side clinical, coverage, and cost comparison for varicose veins of lower extremity.Deep comparison between: Asclera vs Sotradecol with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSotradecol has a higher rate of injection site reactions vs Asclera based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sotradecol but not Asclera, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Asclera
Sotradecol
At A Glance
IV injection
Every 1-2 weeks
Sclerosing agent
IV injection
Sclerosing agent
Indications
- Varicose veins of lower extremity
- Varicose veins of lower extremity
Dosing
Spider veins (<=1 mm) Use Asclera 0.5%, 0.1-0.3 mL per injection IV, no more than 10 mL per session; maintain compression for 2-3 days after treatment.
Reticular veins (1-3 mm) Use Asclera 1%, 0.1-0.3 mL per injection IV, no more than 10 mL per session; maintain compression for 5-7 days after treatment.
Varicose veins of lower extremity 1% solution for most varicosities; 3% solution preferred for larger varicosities; 0.5 mL to 2 mL per injection (1 mL preferred maximum); maximum 10 mL per single treatment; intravenous use only.
Contraindications
- Known allergy to polidocanol
- Acute thromboembolic diseases
- Previous hypersensitivity reaction to sodium tetradecyl sulfate
- Acute superficial thrombophlebitis
- Valvular or deep vein incompetence
- Huge superficial veins with wide open communications to deeper veins
- Phlebitis migrans
- Acute cellulitis
- Allergic conditions
- Acute infections
- Varicosities caused by abdominal or pelvic tumors unless the tumor has been removed
- Bedridden patients
- Uncontrolled systemic diseases including diabetes, toxic hyperthyroidism, tuberculosis, asthma, neoplasm, sepsis, blood dyscrasias, and acute respiratory or skin diseases
Adverse Reactions
Most common (>=3%) Injection site haematoma, irritation, discoloration, pain, pruritus, warmth, neovascularisation, thrombosis
Postmarketing Anaphylactic shock, angioedema, urticaria, asthma, cerebrovascular accident, migraine, paresthesia, loss of consciousness, cardiac arrest, palpitations, deep vein thrombosis, pulmonary embolism, vasculitis, dyspnea, skin hyperpigmentation, injection site necrosis, nerve injury
Most common Pain, urticaria, ulceration at injection site, permanent discoloration along the sclerosed vein segment, headache, nausea, vomiting
Serious Sloughing and necrosis of tissue following extravasation, anaphylactic shock, hives, asthma, hay fever, cerebrovascular accident, myocardial infarction, fatal pulmonary embolism
Pharmacology
Sclerosing agent; polidocanol locally damages the endothelium of blood vessels, inducing platelet aggregation and fibrin occlusion of the vessel, which is subsequently replaced by connective fibrous tissue.
Sodium tetradecyl sulfate is a sclerosing agent; intravenous injection causes intima inflammation and thrombus formation that typically occludes the injected vein, with subsequent fibrous tissue formation resulting in partial or complete vein obliteration.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Asclera
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Sotradecol
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Asclera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Sotradecol
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Asclera
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Sotradecol
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Asclera.
No savings programs available for Sotradecol.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AscleraView full Asclera profile
SotradecolView full Sotradecol profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.